Breaking through treatment-resistant depression often requires interventions that operate through entirely different biological pathways than conventional medications. Spravato (esketamine nasal spray) delivers this alternative approach with rapid-acting mechanisms that can provide relief when standard antidepressants have repeatedly failed. Spravato covered by Cigna enables you to access this transformative therapy while leveraging your insurance benefits to manage expenses. At Good Health Psychological Services, we assist Cigna members in navigating the coverage pathway for Spravato treatment, handling all authorization complexities and providing this clinically supervised intervention for individuals struggling with depression that hasn’t yielded to traditional pharmaceutical approaches.
Our clinical team possesses deep familiarity with Cigna’s specific documentation requirements and approval processes for specialty mental health medications. We construct thorough authorization packages, maintain direct communication channels with Cigna’s review departments, and pursue appeals strategically when coverage determinations require additional advocacy.
Understanding Cigna Coverage for Spravato Therapy
Cigna organizes prescription medication benefits through a formulary that assigns drugs to tiers based on therapeutic value, alternatives, and cost. Spravato is placed in the specialty medication tier due to its novel mechanism, clinical supervision requirement, and second-line treatment for resistant depression. This involves both pharmaceutical coverage for the medication and medical service coverage for administration and monitoring.
Cigna requires prior authorization for Spravato across all plans, assessing whether you meet criteria such as a major depressive disorder diagnosis, inadequate response to prior antidepressants, and any medical conditions that may make Spravato unsafe. Our practice compiles detailed clinical documentation that aligns with Cigna’s evaluation protocols, ensuring we meet all requirements for authorization.
Spravato and Its Mechanism for Depression
Spravato (esketamine) introduces an entirely novel pharmacological approach to depression treatment, becoming the first new class of antidepressant approved by federal regulators in multiple decades. Where established antidepressants work by increasing availability of monoamine neurotransmitters like serotonin and norepinephrine, Spravato modulates the glutamate system—the brain’s primary excitatory neurotransmitter network involved in learning, memory formation, and neural adaptability.
The medication functions as an NMDA receptor antagonist, triggering cascades that promote rapid synaptogenesis and strengthen neural circuit connections. This neuroplasticity enhancement can produce measurable symptom improvements within hours to several days, contrasting sharply with the month-long waiting periods typical of traditional antidepressants. For individuals experiencing severe, persistent depression, this rapid action timeline offers meaningful relief during a compressed timeframe.
Qualifying for Spravato Coverage Under Cigna
Treatment-Resistant Depression Criteria
Cigna defines qualifying treatment-resistant depression as depression that has not responded adequately to a minimum of two different antidepressant medications from distinct pharmacological classes. Each failed trial must have been conducted at a therapeutic dose for an appropriate duration—typically six to eight weeks—ensuring that inadequate response reflects true medication failure rather than insufficient dosing or premature discontinuation.
Documentation supporting your authorization must itemize specific medications tried, precise daily dosages achieved, exact treatment durations, and clinical assessments of response or lack thereof. Our systematic approach to treatment documentation captures these specifics throughout your care, creating authorization-ready records when Spravato becomes clinically indicated.
Medical Necessity Documentation
Beyond demonstrating treatment resistance, Cigna authorization requests require comprehensive clinical context including depression severity scores from standardized assessment instruments, detailed functional impairment descriptions across occupational, social, and personal domains, psychiatric history encompassing any prior hospitalizations or urgent interventions, and comprehensive medical history excluding contraindications like inadequately managed hypertension or active substance use disorders.
We synthesize this information into cohesive clinical submissions that present a clear narrative explaining why Spravato represents the appropriate and necessary next intervention for your particular clinical presentation.
Prior Authorization Process
Once we determine Spravato is clinically appropriate for your treatment-resistant depression, we initiate prior authorization by submitting detailed requests to Cigna’s pharmacy benefit management division. Our submissions include your complete chronological antidepressant history with response assessments, current symptom severity documentation using validated rating scales, functional capacity evaluations demonstrating real-world impact, and clinical rationale explaining why Spravato specifically is medically necessary at this juncture.
Cigna typically processes these requests within five to ten business days. When authorizations are denied, we immediately file appeals incorporating additional clinical evidence, requesting expedited review timelines when clinical urgency warrants, and arranging peer-to-peer discussions between our psychiatrist and Cigna’s medical reviewers to address specific concerns or questions about your case.
The Spravato Treatment Process with Cigna Coverage
Initial Treatment Phase
Spravato treatment launches with an induction phase involving twice-weekly administration sessions over the first four weeks of therapy. Each treatment appointment occurs in our certified clinical facility where you self-administer the nasal spray device under direct medical supervision, then remain in the facility for a mandatory two-hour observation period as required by FDA safety regulations and reinforced by insurance coverage stipulations.
Throughout the observation window, our clinical staff monitors your vital signs, watches for potential adverse effects including dissociative experiences or sedation, and ensures you return to baseline functioning before discharge. Most patients tolerate the medication well, with any side effects typically diminishing before the monitoring period concludes.
Maintenance Treatment Schedule
Following successful completion of the induction phase, treatment frequency adjusts according to your individual clinical response and symptom stability. Some patients maintain weekly sessions for extended periods, while others gradually transition to every-other-week or monthly maintenance treatments. Cigna provides ongoing coverage for maintenance phases when continued medical necessity is demonstrated through regular symptom monitoring and functional outcome assessments.
We track your depression symptoms systematically using standardized measurement tools, generating quantitative data that supports ongoing authorization renewals and documents that Spravato continues providing meaningful therapeutic benefit justifying continued treatment.
Monitoring and Safety Protocols
Each Spravato session incorporates comprehensive safety procedures including baseline blood pressure and heart rate measurements, continuous staff availability throughout the observation period, systematic monitoring for dissociative symptoms, sedation, or cardiovascular changes, and thorough documentation of treatment tolerability and response. These protocols fulfill FDA safety requirements while satisfying Cigna’s coverage conditions.
Because Spravato can cause temporary sedation and altered perception, patients cannot operate vehicles following treatment. Arranging reliable transportation for each session constitutes a mandatory treatment requirement.
WHAT WE ACHIEVED
Why Us
- Our practice is patient-centered and individualized to meet the needs of each of our patients
- Our patients' health and well-being are always our number 1 priority
- Our providers have multi-layered experience with various mental health challenges
PATIENTS SERVICED
YEARS IN BUSINESS
Why Choose Us for Spravato Treatment with Cigna
Insurance Authorization Expertise
Securing Spravato coverage through Cigna demands meticulous clinical documentation presented in accordance with their specific review criteria. Our practice specializes in treatment-resistant depression cases, maintaining detailed records that comprehensively address Cigna’s evidence requirements. We understand precisely what information their medical reviewers need and structure authorization submissions to provide it efficiently.
When coverage challenges emerge, we advocate persistently through appeals processes, supplementing initial submissions with additional clinical context, obtaining supporting documentation from other providers when beneficial, and engaging in direct physician communication with Cigna medical directors to resolve specific coverage concerns.
Certified Spravato Treatment Facility
Federal regulations restrict Spravato administration to healthcare facilities that have completed certification demonstrating appropriate monitoring capabilities, trained staff, and established safety protocols. Good Health maintains full certification with all required monitoring equipment, comprehensively trained clinical personnel, and systematic safety procedures. Our certification ensures complete compliance with both regulatory mandates and Cigna’s facility qualification requirements, preventing coverage denials related to treatment setting.
We’ve designed our Spravato treatment environment specifically to promote comfort and relaxation during the two-hour observation periods, recognizing that a calming atmosphere enhances the overall treatment experience.
Experienced Treatment-Resistant Depression Care
Our psychiatric team concentrates specifically on complex depression cases that have not responded to conventional treatment approaches. This focused expertise enables accurate evaluation of whether Spravato represents the optimal next intervention for your unique clinical situation, or whether alternative strategies might offer superior outcomes. We integrate Spravato into comprehensive treatment plans rather than viewing it as an isolated intervention, ensuring all aspects of your depression receive coordinated attention.
Comprehensive Mental Health Services
Beyond Spravato administration, we provide fully integrated psychiatric care including ongoing medication management for any concurrent psychotropic prescriptions, evidence-based psychotherapy modalities addressing psychological and behavioral depression components, care coordination with other mental health professionals or medical providers on your treatment team, and access to additional treatment-resistant depression interventions including Transcranial Magnetic Stimulation when clinically appropriate.
This integrated care model ensures holistic attention to all dimensions of your mental health rather than narrowly focusing on a single treatment modality.
Flexible Scheduling and Accessible Location
We recognize that attending twice-weekly treatment sessions during the induction phase requires significant time commitment and schedule flexibility. Our Brooklyn practice offers varied appointment times including early morning, midday, and early evening slots to accommodate working professionals, caregivers, and individuals with diverse scheduling constraints. Convenient public transportation access further reduces logistical barriers to maintaining consistent treatment attendance.
Testimonials
Try Treatment-Resistant Depression Therapy With Spravato
Living with treatment-resistant depression creates progressive deterioration across every life dimension—personal relationships suffer under the strain of unrelenting symptoms, professional performance declines from impaired concentration and motivation, and hope gradually erodes with each unsuccessful treatment attempt. When multiple antidepressant trials have failed to deliver relief, Spravato offers a mechanistically different approach that may finally break through the depression that has dominated your existence.
Understanding that Spravato is covered by Cigna when appropriate medical necessity criteria are satisfied creates realistic pathways to accessing this innovative intervention. The authorization process requires specialized knowledge and persistent advocacy, but our practice manages these administrative challenges while you focus on your recovery journey.
If you’re a Cigna member in Brooklyn struggling with depression that hasn’t responded adequately to multiple antidepressant medications, contact Good Health Psychological Services today. With advanced treatment technologies and expert insurance navigation working in coordination, meaningful recovery from treatment-resistant depression becomes an achievable goal rather than an impossible aspiration.
Don't hesitate to contact us
Have any questions?
Please complete the form below and we will get right back to you.